Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,204.13
(
0.96%
)
US TECH 100
26,692.40
(
0.87%
)
Dow Jones
49,647.77
(
1.61%
)
Brent Oil
110.30
(
-1.85%
)
Bitcoin
76,354.04
(
0.76%
)
News Focus
News Focus
Post# of 257472
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122913
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 250551

Monday, 02/12/2024 11:49:41 AM

Monday, February 12, 2024 11:49:41 AM

Post# of 257472
GILD acquires CBAY for $32.50 cash—a 27% premium to Friday’s close:

https://finance.yahoo.com/news/gilead-sciences-expands-liver-portfolio-133000610.html

CBAY has no approved drugs, but CBAY’s Seladelpar is under FDA review for PBC with a PDUFA date of 8/14/24. Seladelpar previously failed in NASH.

The nominal deal value is $4.3B.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today